BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19483413)

  • 1. [Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity].
    Kasuga J; Oyama T; Nakagome I; Aoyama A; Sako K; Makishima M; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
    Yakugaku Zasshi; 2009 Jun; 129(6):709-18. PubMed ID: 19483413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
    Kasuga J; Nakagome I; Aoyama A; Sako K; Ishizawa M; Ogura M; Makishima M; Hirono S; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2007 Aug; 15(15):5177-90. PubMed ID: 17532641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel biphenylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) delta selective antagonists.
    Kasuga J; Ishida S; Yamasaki D; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6595-9. PubMed ID: 19853439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures.
    Oyama T; Toyota K; Waku T; Hirakawa Y; Nagasawa N; Kasuga JI; Hashimoto Y; Miyachi H; Morikawa K
    Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):786-95. PubMed ID: 19622862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and structure-activity relationship study of 2-piperazinyl-benzothiazole derivatives as potent and selective PPARδ agonists.
    Kato T; Ohara T; Suzuki N; Naya N; Fukao K; Tokuyama R; Muto S; Fukasawa H; Itai A; Matsumura KI
    Bioorg Med Chem; 2023 Mar; 82():117215. PubMed ID: 36840990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo.
    Ham J; Hwang H; Kim E; Kim JA; Cho SJ; Ko J; Lee W; Lee J; Holla H; Banerjee J; Kim S; Yang I; Lee HJ; Shin K; Choi H; Nam SJ; Tak J; Hahn D; Oh T; Won DH; Lee TG; Choi J; Park MS; Seok C; Chin J; Kang H
    Eur J Med Chem; 2012 Jul; 53():190-202. PubMed ID: 22534184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
    Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
    Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bidirectional fluorescence properties of pyrene-based peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist.
    Ban S; Oyama T; Kasuga J; Ohgane K; Nishio Y; Morikawa K; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2012 Jun; 20(11):3460-4. PubMed ID: 22551628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part.
    Kasuga J; Oyama T; Hirakawa Y; Makishima M; Morikawa K; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4525-8. PubMed ID: 18662876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
    Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
    J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
    Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
    Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands.
    Miyachi H
    Curr Med Chem; 2007; 14(22):2335-43. PubMed ID: 17896982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.
    Bratton LD; Filzen GF; Geyer A; Hoffman JK; Lu G; Pulaski J; Trivedi BK; Unangst PC; Xu X
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3624-9. PubMed ID: 17498950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Okazaki S; Shioi R; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem; 2016 Nov; 24(21):5455-5461. PubMed ID: 27622746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
    Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
    Kasuga J; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2006 Feb; 16(3):554-8. PubMed ID: 16275077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Structural Optimization of Dual FXR/PPARδ Activators.
    Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
    J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.